Global Alpha Capital Management Ltd. lifted its holdings in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 70.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,101 shares of the medical instruments supplier's stock after purchasing an additional 7,076 shares during the quarter. Global Alpha Capital Management Ltd.'s holdings in Haemonetics were worth $1,335,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in HAE. AMG National Trust Bank acquired a new position in shares of Haemonetics in the 4th quarter valued at about $746,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Haemonetics in the fourth quarter worth $284,000. Raymond James Financial Inc. purchased a new position in shares of Haemonetics in the 4th quarter valued at $19,002,000. Arizona State Retirement System raised its stake in shares of Haemonetics by 1.2% in the 4th quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier's stock valued at $1,160,000 after acquiring an additional 181 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Haemonetics by 1.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 551,193 shares of the medical instruments supplier's stock valued at $43,037,000 after purchasing an additional 8,477 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.
Haemonetics Stock Performance
Shares of NYSE:HAE traded down $2.53 on Wednesday, reaching $65.77. 1,002,832 shares of the company's stock were exchanged, compared to its average volume of 1,013,738. The firm has a market capitalization of $3.30 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a fifty-two week low of $58.80 and a fifty-two week high of $97.97. The business's 50-day moving average is $69.40 and its two-hundred day moving average is $75.63. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35.
Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, equities research analysts forecast that Haemonetics Co. will post 4.55 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of research firms have recently issued reports on HAE. Raymond James reiterated a "strong-buy" rating and issued a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. JMP Securities dropped their price target on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research note on Friday, February 7th. JPMorgan Chase & Co. began coverage on Haemonetics in a research note on Friday, December 6th. They set an "overweight" rating and a $116.00 target price for the company. Needham & Company LLC cut their price target on Haemonetics from $112.00 to $108.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Finally, Bank of America downgraded Haemonetics from a "neutral" rating to an "underperform" rating and dropped their price objective for the stock from $95.00 to $68.00 in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $101.67.
Read Our Latest Stock Report on Haemonetics
Haemonetics Company Profile
(
Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Featured Articles
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
